Article
Oncology
Paula Cabello, Sandra Torres-Ruiz, Anna Adam-Artigues, Jaume Fores-Martos, Maria Teresa Martinez, Cristina Hernando, Sandra Zazo, Juan Madoz-Gurpide, Ana Rovira, Octavio Burgues, Federico Rojo, Joan Albanell, Ana Lluch, Begona Bermejo, Juan Miguel Cejalvo, Pilar Eroles
Summary: The expression of miR-146a-5p is associated with the efficacy and survival of HER2-positive breast cancer patients treated with trastuzumab. Increased expression of miR-146a-5p leads to resistance to trastuzumab and enhances cell migration and angiogenesis, promoting cell cycle progression. Furthermore, exosomes from trastuzumab-resistant cells, which contain high levels of miR-146a-5p expression, can transfer resistance properties to other cells.
Article
Cell & Tissue Engineering
Yan Qiu, Libo Yang, Honghong Liu, Xiaobo Luo
Summary: The use of the anti-HER2 drug trastuzumab has significantly improved the prognosis of HER2-positive breast cancer patients, but 50% of patients relapse due to trastuzumab resistance, which is closely related to the presence of breast cancer stem cells (BCSCs). BCSCs are resistant to conventional therapy and may drive distant metastasis and cancer relapse.
Article
Immunology
Yi Xiao, Jiahan Ding, Dachang Ma, Sheng Chen, Xun Li, Keda Yu
Summary: This study found that the HER2/CEP17 ratio, CD8 levels, and histological grade were significantly correlated with pathological complete response (pCR) in dual-targeted neoadjuvant treatment. The combined model using these three markers provided a better predictive value for pCR than the individual markers alone, indicating that the immunological effect partially mediates the predictive impact of neoadjuvant treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Fei Xing, Hongli Gao, Guanglei Chen, Lisha Sun, Jiayi Sun, Xinbo Qiao, Jinqi Xue, Caigang Liu
Summary: This study uncovered the role of CMTM6 in trastuzumab-resistant HER2+ breast cancer. High expression of CMTM6 was associated with worse survival and affected the stability of HER2 protein. These findings suggest CMTM6 as a potential prognostic marker and therapeutic target for overcoming trastuzumab resistance.
Article
Oncology
Ji Young You, Kyoung Hwa Park, Eun Sook Lee, Youngmee Kwon, Kyoung Tae Kim, Seungyoon Nam, Dong Hee Kim, Jeoung Won Bae
Summary: This study aimed to identify differentially expressed genes and pathways associated with good responses to anti-HER2 therapy and predict drug response in HER2-positive breast cancer patients undergoing neoadjuvant systemic therapy with trastuzumab. Analysis of RNA from tissue samples and cell lines revealed 6,656 differentially expressed genes, with 3,224 upregulated and 3,432 downregulated genes in trastuzumab-resistant cell lines. Changes in expression of 34 genes in various pathways were found to be related to the response to trastuzumab-containing treatment, affecting adhesion, extracellular matrix interactions, and phagosome action. This study provides insights into breast cancer signaling and potential predictions of therapeutic response to targeted therapies.
Article
Oncology
Neil T. Conlon, Jeffrey J. Kooijman, Suzanne J. C. van Gerwen, Winfried R. Mulder, Guido J. R. Zaman, Irmina Diala, Lisa D. Eli, Alshad S. Lalani, John Crown, Denis M. Collins
Summary: The study compared the anti-proliferative effects of three HER2-targeted drugs on cancer cell lines, showing neratinib to be the most effective against HER2-positive as well as HER2 and EGFR mutant cells. The research also identified novel biomarkers associated with drug response and resistance.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Nicola Cosgrove, Alex J. Eustace, Peter O'Donovan, Stephen F. Madden, Bruce Moran, John Crown, Brian Moulton, Patrick G. Morris, Liam Grogan, Oscar Breathnach, Colm Power, Michael Allen, Janice M. Walshe, Arnold D. Hill, Anna Blumel, Darren O'Connor, Sudipto Das, Malgorzata Milewska, Joanna Fay, Elaine Kay, Sinead Toomey, Bryan T. Hennessy, Simon J. Furney
Summary: This study suggests that age, estrogen receptor status, and level of immune cell infiltration may play important roles in predicting the response to neoadjuvant therapy in HER2-positive breast cancer. Clonal evolution analysis reveals the presence of therapy resistant subclones. APOBEC-associated mutagenesis may mediate the immunogenic phenotype in HER2-negative/HER2-positive subtype.
Review
Pharmacology & Pharmacy
Xiaofan Wu, Hongjian Yang, Xingfei Yu, Jiang-Jiang Qin
Summary: Breast cancer is a common malignancy in women, and HER2 overexpression is associated with poor prognosis. Pertuzumab and trastuzumab are the primary treatment options for early-stage HER2-positive breast cancer, and antibody-drug conjugates and tyrosine kinase inhibitors improve prognosis for metastatic breast cancer patients. However, resistance to targeted therapy is an issue that needs to be addressed.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Luciana de Moura Leite, Marcelle Goldner Cesca, Monique Celeste Tavares, Debora Maciel Santana, Erick Figueiredo Saldanha, Paula Tavares Guimaraes, Daniella Dias Silva Sa, Maria Fernanda Evangelista Simoes, Rafael Lima Viana, Francisca Giselle Rocha, Simone Klog Loose, Sinara Figueiredo Silva, Rafaela Pirolli, Camilla Albina Zanco Fogassa, Bruna Raphaeli Silva Mattos, Fernando Augusto Batista Campos, Solange Moraes Sanches, Vladmir Claudio Cordeiro de Lima, Noam Falbel Ponde
Summary: Our study does not support HER2-low as a biologically distinct subtype of breast cancer, showing no prognostic value on survival outcomes and no predictive effect for pathological complete response after conventional neoadjuvant chemotherapy.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Oncology
Ilana Schlam, Paolo Tarantino, Sara M. Tolaney
Summary: This article summarizes the resistance mechanisms to HER2-targeted treatments and discusses the potential strategies to overcome them in order to improve outcomes for breast cancer patients.
Article
Oncology
Laura Diaz-Gil, Fara Braso-Maristany, Claudriana Locatelli, Ariana Centa, Balasz Gyorffy, Alberto Ocana, Aleix Prat, Atanasio Pandiella
Summary: Trastuzumab-based therapies are effective for HER2+ breast cancer, but some tumors develop resistance. Besides HER2 overexpression, other genes can predict prognosis and treatment response in HER2+ breast cancer patients. The identification of trastuzumab response biomarkers is crucial for patient selection and treatment refinement.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Genetics & Heredity
Nermine H. Zakaria, Doaa Hashad, Marwa H. Saied, Neamat Hegazy, Alyaa Elkayal, Eman Tayae
Summary: The study identified 29 genetic variants in nine genes that were associated with resistance to trastuzumab therapy, including four variants that were repeated in multiple resistant patients. Additionally, mutations in MLH1, SMARCB1, and SMO genes were found only in resistant patients, along with a novel allele in the TP53 gene.
Article
Multidisciplinary Sciences
Sandeep Kumar, Subhasis Das, Jingjing Sun, Yixian Huang, Sunil Kumar Singh, Piush Srivastava, Gautam Sondarva, Rakesh Sathish Nair, Navin Viswakarma, Balaji B. Ganesh, Lei Duan, Carl G. Maki, Kent Hoskins, Oana Danciu, Basabi Rana, Song Li, Ajay Rana
Summary: Researchers designed nanoparticles loaded with MLK3 agonist ceramide (PPP-CNP) and demonstrated that they can activate MLK3, down-regulate the AKT pathway, induce cell death, and overcome resistance in HER2(+) breast cancer.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Editorial Material
Oncology
Alicia F. C. Okines, Nicholas C. Turner
Summary: HER2 amplification heterogeneity is linked to resistance to trastuzumab emtansine in the neoadjuvant setting, highlighting the significance of determining whether varying HER2-positive cancer types require distinct treatment approaches.
Article
Multidisciplinary Sciences
Yuson Wang, Xiaoyan Liu, Keda Yu, Shouping Xu, Pengfei Qiu, Xinwen Zhang, Mozhi Wang, Yingying Xu
Summary: Neoadjuvant therapy (NAT) is recommended for patients with HER2+ BC who have a poor prognosis. The tumor immune microenvironment plays a significant role in the efficacy of NAT, but the relationship between tumor-infiltrating lymphocytes and the response to NAT in HER2+ BC is not yet clear. Our study classified the immune infiltration status of 295 patients into immune-rich and immune-poor phenotypes, with the immune-rich phenotype being significantly associated with pCR. We identified 10 genes that were correlated with both pCR and the immune phenotype, and constructed a generalized non-linear model that successfully predicted response to NAT.
Article
Oncology
Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, Paola Tiberio, Marilena Iorio, Florentine Hilbers, Evandro de Azambujas, Lorena de la Pena, Miguel Izquierdo, Jens Huober, Jose Baselga, Martine Piccart, Filippo G. de Braud, Giovanni Apolone, Paolo Verderio, Maria Grazia Daidone
CLINICAL CANCER RESEARCH
(2019)
Article
Biochemistry & Molecular Biology
Lorenzo Castagnoli, Valeria Cancila, Sandra L. Cordoba-Romero, Simona Faraci, Giovanna Talarico, Beatrice Belmonte, Marilena V. Iorio, Matteo Milani, Tatiana Volpari, Claudia Chiodoni, Alfredo Hidalgo-Miranda, Elda Tagliabue, Claudio Tripodo, Sabina Sangaletti, Massimo Di Nicola, Serenella M. Pupa
Editorial Material
Oncology
Marilena V. Iorio, Dario Palmieri
FRONTIERS IN ONCOLOGY
(2019)
Article
Oncology
Sandra Romero-Cordoba, Elisabetta Meneghini, Milena Sant, Marilena Valeria Iorio, Lucia Sfondrini, Biagio Paolini, Roberto Agresti, Elda Tagliabue, Francesca Bianchi
Review
Biochemistry & Molecular Biology
Giulia Cosentino, Ilaria Plantamura, Alessandra Cataldo, Marilena V. Iorio
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2019)
Article
Biochemistry & Molecular Biology
Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, Marco Silvestri, Jose Baselga, Martine Piccart, Jens Huober, Miguel Izquierdo, Lorena de la Pena, Florentine S. Hilbers, Evandro de Azambuja, Michael Untch, Lajos Pusztai, Kathleen Pritchard, Paolo Nuciforo, Anne Vincent-Salomon, Fraser Symmans, Giovanni Apolone, Filippo G. de Braud, Marilena Iorio, Paolo Verderio, Maria Grazia Daidone
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Oncology
Alessandra Cataldo, Sandra Romero-Cordoba, Ilaria Plantamura, Giulia Cosentino, Alfredo Hidalgo-Miranda, Elda Tagliabue, Marilena Iorio
Article
Cell Biology
Giulia Cosentino, Sandra Romero-Cordoba, Ilaria Plantamura, Alessandra Cataldo, Marilena V. Iorio
Review
Biochemistry & Molecular Biology
Ilaria Plantamura, Alessandra Cataldo, Giulia Cosentino, Marilena V. Iorio
Summary: Despite controversial roles in different cancer types, miR-205 is mainly described as an oncosuppressive miRNA in breast cancer. Its expression decreases from less aggressive to more aggressive subtypes and influences metastasis capability, therapy response, and patient survival. MiR-205 plays a role in breast cancer initiation and progression, stemness maintenance, tumor microenvironment, and may serve as a biomarker with relevance in normal breast physiology. Additionally, some lncRNAs are implicated in breast cancer progression by acting as sponges of miR-205.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Nutrition & Dietetics
Sandra L. Romero-Cordoba, Ivan Salido-Guadarrama, Maria E. Meneses, Giulia Cosentino, Marilena V. Iorio, Elda Tagliabue, Nimbe Torres, Monica Sanchez-Tapia, Myrna Bonilla, Ivan Castillo, Beatriz Petlacalco, Armando R. Tovar, Daniel Martinez-Carrera
Summary: The study reveals that Ganoderma lucidum extracts modulate metabolic pathways related to lipid biosynthesis and degradation, with Gl-2 extract showing a major modulation over gene expression programs similar to simvastatin druggable-target-genes enriched in processes related to human obesity alterations in the liver. Additionally, certain Gl-modulated genes are correlated with Lactobacillus enrichment and the reduction of circulating cholesterol-derived fats. The extracts also induce a decrease in macrophage lipid storage, suggesting a new link between Gl's hypocholesterolemic and prebiotic activity in preventing metabolic disorders associated with hypercholesterolemia.
Review
Chemistry, Medicinal
Orazio Fortunato, Marilena V. Iorio
